Cerepeut

Cerepeut is a biotechnology company focused on developing first-in-class oral small molecule therapeutics that target mitochondrial biology to treat neurodegenerative and age-related diseases. The company's research centers on mitochondrial reverse electron transport (RET), a process in Complex I that drives oxidative stress, reactive oxygen species (ROS) generation, and cellular dysfunction. Cerepeut's lead candidate, CP-235 (also known as CPT or CPT-2008), is an oral small molecule RET inhibitor that binds to the NDUFS3 subunit of Complex I, breaking the pathological feedback loop between phosphorylated tau (pTau) and RET. The company is advancing CP-235 through IND-enabling studies, with plans to target progressive supranuclear palsy (PSP) as its first clinical indication, followed by larger indications such as Alzheimer's disease, Parkinson's disease, and frontotemporal dementia.